Plunkett Research Online: Hansa Biopharma AB

HANSA BIOPHARMA AB (HNSA:MEX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Hansa Biopharma AB is a biopharmaceutical company which develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme bein.....



Hansa Biopharma AB
Ticker: HNSA
Exchange: MEX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 46 46165670
Fax: 46 46127775
Address: Scheelevagen 22
Lund, SE-223 63 Sweden

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biotechnology

Ranks not available
Contacts Description

Hansa Biopharma AB is a biopharmaceutical company which develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme bein.....See More See More

Auditor: KPMG AB
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017 2016 2015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: